Dr. Mark Noar serves the company as Chairman and CEO. He brings to the Board more than 30 years’ experience in hardware and software development and integration in the medical device industry as well as clinical and research-based practice in gastroenterology and surgery. He is the co-inventor of the 3 CPM technology and a host of other inventions and innovations in the fields of interventional endoscopy and medical education and simulation. He has directed a number of clinical research projects, including the ability of EGG to screen, predict successful treatment outcomes and avoid complications with surgical intervention for GERD patients. He has authored many publications and produced video educational materials. Acting as an advisor to the pharmaceutical and medical device industries, he has a successful history of technology introduction and trend setting in medical device development and reimbursement. Since joining 3 CPM, he has overseen the development and patenting of advancements of the EGG technology, including the integration of computer-based AI interpretation and diagnostics, open architecture Research-focused EGG used by the NIH, complementary software products and an ample pipeline of future technology advances that will keep 3 CPM in the forefront of the industry in the foreseeable future.
Board of Directors
The 3CPM Company was formed in January 1998 to exploit the proprietary Electrogastrogram (EGG) technology developed by one of its founders, Kenneth Koch, MD, and to capitalize on the resulting market opportunity.
Kenneth L. Koch, MD is Professor of Medicine, Section on Gastroenterology and Hepatology, Wake Forest Baptist Medical Center. He has a career-long interest in understanding physiological and pathophysiological mechanisms of nausea and gastroparesis. He has studied extensively gastric myoelectrical activity (GMA) using cutaneous electrodes in the study of normal 3 cpm GMA and gastric dysthymias in patients with nausea and vomiting syndromes. He advanced the development of clinical electrogastrography with straightforward tests of GMA and analyses of the recordings and is the co-inventor of the 3 CPM technology. He is a founder of the 3 CPM Company for which he is a shareholder and director and serves as the Science Officer. In addition, he is a Principal Investigator for the NIH-sponsored Gastroparesis Clinic Research Consortium and has published over 160 peer-reviewed scientific papers, 47 book chapters and 7 books.
From 1984 to 1990 he was the President of Industrial Fermentation Genetics, a biotech Company which manufactured and sold specialty proteins derived from genetic engineering. The Company was acquired in 1990. From 1982 to 1984 he was the President of California Integrated Diagnostics, a manufacturer of kits for the detection of sexually transmitted diseases. The Company was acquired in 1984 by a larger competitor. He was also a senior consultant with Arthur D. Little, Inc. and was involved with strategic and marketing assignments with numerous companies in the medical area. Mr. DiDario currently serves on the Board of three companies with a technology focus and products for the financial services and RFID/GPS asset tracking markets.
Since 2008 Mr. Jones is “The Serial CFO” where he provides interim and consulting CFO services to a number of embryonic Companies in Silicon Valley including a laser manufacturer, a medical device company, and several small businesses which require finance and/or accounting advice. From 2004 through 2008, he was a Director for the CPA firm Louie and Wong. From 1997 through 2004, he was the CFO of 3CPM through 2004. Prior to that he was the CFO for Maven Labs, Inc. from 1992 to 1997, where he was responsible for finance, accounting, investor relations, treasury and information systems functions. From 1990 to 1992, he was a consultant to the Chairman of Network Solutions, Inc., a Company that engaged in the exclusive registration of Internet addresses. Mr. Jones is also Board Chair for Main Street Launch.
Carlos Babini joined USGI Medical as President and CEO in 2017. A world-class commercialization expert, Carlos brings more than 25 years of successful leadership experience to USGI, with distinguished performance in both public and private sectors of medical device companies. Previously he served as Vice President of AirSeal® System Commercialization for Conmed Corporation, and Chief Commercialization Officer at SurgiQuest, Inc., a medical company offering surgical devices and equipment for laparoscopic and robotic surgical procedures, prior to being acquired by Conmed. Carlos also served as President, International for Curon, Inc. and Chief Sales and Marketing Officer of the medical segment of Vision Sciences Inc., and held various senior management positions at United States Surgical Corporation prior to its acquisition by Tyco, and subsequently by Medtronic.